Drug lookup | Fillwise

RISEDRONATE SODIUM

20 general benefit · 3 not a benefit

Other products in the same Health Canada class (M05B, M05BA) — coverage varies; not interchangeable

Alendronate (Fosamax): general benefit, Not a benefit
Clodronate (Ostac): limited Use 280, 358, 359, Not a benefit
Etidronate (Didronel): limited Use 236, 237, Not a benefit
Zoledronic acid (Aclasta): limited Use 319, 436, 523, Not a benefit
Pamidronate (Aredia): not a benefit
Alendronate + cholecalciferol (Fosavance): general benefit

1 more in the class list below

Teva-Risedronate · DIN 02298376 · 5mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Teva-Risedronate · DIN 02298376 Manufacturer: Teva Canada Limited; listing date 2010-04-23 Health Canada: Marketed since 2011-06-03 · brand TEVA-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM MONOHYDRATE) 5 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Teva-Risedronate: Formulary list price $1.8445/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.8445 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78367 · Verify on the e-Formulary ↗ (DIN 02298376)

Source record

DIN 02298376: Teva-Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000372; group id 952; item number 2259; lccId None; manufacturer id TEV Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.8445; ministry $1.8445 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02298376 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78367

Interchangeable products

Actonel · DIN 02242518 · not recorded

Shortage status: resolved shortage (ended 2026-06-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02298376

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Risedronate · DIN 02298384 · 30mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Teva-Risedronate · DIN 02298384 Manufacturer: Teva Canada Limited; listing date 2010-04-23 Health Canada: Marketed since 2011-06-03 · brand TEVA-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM MONOHYDRATE) 30 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Teva-Risedronate: Formulary list price $11.3807/unit (unit not stated in source; not the patient's cost)

Ministry pays: $11.3807 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 02298384: Teva-Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000340; group id 952; item number 2260; lccId None; manufacturer id TEV Source form: Tab; strength: 30mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $11.3807; ministry $11.3807 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02298384 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78368

Interchangeable products

Actonel · DIN 02239146 · not recorded

Shortage status: discontinued (2025-04-07, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02298384

Shortage record checked 2026-09-13T08:10:21.292534+00:00

AA-Risedronate DR · DIN 02493268 · 35mg · DR tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

AA-Risedronate DR · DIN 02493268 Manufacturer: A A Pharma Inc.; listing date 2021-07-30 Health Canada: Marketed since 2023-09-08 · brand AA-RISEDRONATE DR · ATC M05BA07 RISEDRONIC ACID · form Tablet (delayed-release) · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Aa pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

AA-Risedronate DR: Formulary list price $2.9663/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.9663 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98324 · Verify on the e-Formulary ↗ (DIN 02493268)

Source record

DIN 02493268: AA-Risedronate DR Raw flags: chronicUseMed=Y, sec3=Y Item: 920000656; group id 952; item number 2258; lccId None; manufacturer id AAP Source form: DR Tab; strength: 35mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $2.9663; ministry $2.9663 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02493268 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98324

Interchangeable products

Actonel DR · DIN 02370417 · $2.9663

Shortage status: resolved shortage (ended 2025-03-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02493268

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Actonel DR · DIN 02370417 · 35mg · DR tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Savings card: RxHelp ONE lists Actonel DR (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)

1 brand, same coverage

Actonel DR · DIN 02370417 Manufacturer: Warner Chilcott Canada Co.; listing date 2012-02-29 Health Canada: Marketed since 2025-05-22 · brand ACTONEL DR · ATC M05BA07 RISEDRONIC ACID · form Tablet (delayed-release) · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Abbvie corporation · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $2.9663 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85557 · Verify on the e-Formulary ↗ (DIN 02370417)

Source record

DIN 02370417: Actonel DR Raw flags: chronicUseMed=Y, sec3=Y Item: 920000656; group id 952; item number 2258; lccId None; manufacturer id WAR Source form: DR Tab; strength: 35mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $11.8653; ministry $2.9663 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02370417 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85557

Interchangeable products

AA-Risedronate DR · DIN 02493268 · $2.9663

Shortage status: resolved shortage (ended 2020-06-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02370417

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Risedronate · DIN 02353687 · 35mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Apo-Risedronate · DIN 02353687 Manufacturer: Apotex Inc.; listing date 2010-10-28 Health Canada: Marketed since 2012-06-20 · brand APO-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Risedronate: Formulary list price $1.6764/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.6764 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83888 · Verify on the e-Formulary ↗ (DIN 02353687)

Source record

DIN 02353687: Apo-Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000430; group id 952; item number 2261; lccId None; manufacturer id APX Source form: Tab; strength: 35mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.6764; ministry $1.6764 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02353687 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83888

Interchangeable products

Actonel · DIN 02246896 · not recorded Auro-Risedronate · DIN 02406306 · $1.6764 Jamp-Risedronate · DIN 02368552 · $1.6764 PMS-Risedronate · DIN 02302209 · $1.6764 Ratio-Risedronate · DIN 02319861 · $1.6764 Risedronate · DIN 02370255 · $1.6764 Risedronate · DIN 02411407 · $1.6764 Riva-Risedronate · DIN 02341077 · $1.6764 Sandoz Risedronate · DIN 02327295 · $1.6764 Teva-Risedronate · DIN 02298392 · $1.6764

Shortage status: resolved shortage (ended 2018-12-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02353687

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Risedronate · DIN 02406306 · 35mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Auro-Risedronate · DIN 02406306 Manufacturer: Auro Pharma Inc.; listing date 2013-09-27 Health Canada: Marketed since 2013-07-08 · brand AURO-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Auro pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Auro-Risedronate: Formulary list price $1.6764/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.6764 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89102 · Verify on the e-Formulary ↗ (DIN 02406306)

Source record

DIN 02406306: Auro-Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000430; group id 952; item number 2261; lccId None; manufacturer id AUR Source form: Tab; strength: 35mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.6764; ministry $1.6764 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02406306 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89102

Interchangeable products

Actonel · DIN 02246896 · not recorded Apo-Risedronate · DIN 02353687 · $1.6764 Jamp-Risedronate · DIN 02368552 · $1.6764 PMS-Risedronate · DIN 02302209 · $1.6764 Ratio-Risedronate · DIN 02319861 · $1.6764 Risedronate · DIN 02370255 · $1.6764 Risedronate · DIN 02411407 · $1.6764 Riva-Risedronate · DIN 02341077 · $1.6764 Sandoz Risedronate · DIN 02327295 · $1.6764 Teva-Risedronate · DIN 02298392 · $1.6764

Shortage status: resolved shortage (ended 2024-11-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02406306

Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Risedronate · DIN 02302209 · 35mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

PMS-Risedronate · DIN 02302209 Manufacturer: Pharmascience Inc.; listing date 2010-10-28 Health Canada: Marketed since 2010-07-27 · brand PMS-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Pharmascience inc · schedule Prescription

Check this DIN again · Health Canada product record

PMS-Risedronate: Formulary list price $1.6764/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.6764 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78754 · Verify on the e-Formulary ↗ (DIN 02302209)

Source record

DIN 02302209: PMS-Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000430; group id 952; item number 2261; lccId None; manufacturer id PMS Source form: Tab; strength: 35mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.6764; ministry $1.6764 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02302209 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78754

Interchangeable products

Actonel · DIN 02246896 · not recorded Apo-Risedronate · DIN 02353687 · $1.6764 Auro-Risedronate · DIN 02406306 · $1.6764 Jamp-Risedronate · DIN 02368552 · $1.6764 Ratio-Risedronate · DIN 02319861 · $1.6764 Risedronate · DIN 02370255 · $1.6764 Risedronate · DIN 02411407 · $1.6764 Riva-Risedronate · DIN 02341077 · $1.6764 Sandoz Risedronate · DIN 02327295 · $1.6764 Teva-Risedronate · DIN 02298392 · $1.6764

Shortage status: resolved shortage (ended 2024-08-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02302209

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Risedronate · DIN 02370255 · 35mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Risedronate · DIN 02370255 Manufacturer: Sanis Health Inc.; listing date 2020-06-30 Health Canada: Marketed since 2025-02-13 · brand RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Sanis health inc · schedule Prescription

Check this DIN again · Health Canada product record

Risedronate: Formulary list price $1.6764/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.6764 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85541 · Verify on the e-Formulary ↗ (DIN 02370255)

Source record

DIN 02370255: Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000430; group id 952; item number 2261; lccId None; manufacturer id SAI Source form: Tab; strength: 35mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.6764; ministry $1.6764 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02370255 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85541

Interchangeable products

Actonel · DIN 02246896 · not recorded Apo-Risedronate · DIN 02353687 · $1.6764 Auro-Risedronate · DIN 02406306 · $1.6764 Jamp-Risedronate · DIN 02368552 · $1.6764 PMS-Risedronate · DIN 02302209 · $1.6764 Ratio-Risedronate · DIN 02319861 · $1.6764 Risedronate · DIN 02411407 · $1.6764 Riva-Risedronate · DIN 02341077 · $1.6764 Sandoz Risedronate · DIN 02327295 · $1.6764 Teva-Risedronate · DIN 02298392 · $1.6764

Shortage status: resolved shortage (ended 2026-03-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02370255

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Risedronate · DIN 02411407 · 35mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Risedronate · DIN 02411407 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-05-29 Health Canada: Marketed since 2024-02-01 · brand RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM MONOHYDRATE) 35 MG · company Sivem pharmaceuticals ulc · schedule Prescription

Check this DIN again · Health Canada product record

Risedronate: Formulary list price $1.6764/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.6764 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89602 · Verify on the e-Formulary ↗ (DIN 02411407)

Source record

DIN 02411407: Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000430; group id 952; item number 2261; lccId None; manufacturer id SIV Source form: Tab; strength: 35mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.6764; ministry $1.6764 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02411407 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89602

Interchangeable products

Actonel · DIN 02246896 · not recorded Apo-Risedronate · DIN 02353687 · $1.6764 Auro-Risedronate · DIN 02406306 · $1.6764 Jamp-Risedronate · DIN 02368552 · $1.6764 PMS-Risedronate · DIN 02302209 · $1.6764 Ratio-Risedronate · DIN 02319861 · $1.6764 Risedronate · DIN 02370255 · $1.6764 Riva-Risedronate · DIN 02341077 · $1.6764 Sandoz Risedronate · DIN 02327295 · $1.6764 Teva-Risedronate · DIN 02298392 · $1.6764

Shortage status: resolved shortage (ended 2024-02-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02411407

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Riva-Risedronate · DIN 02341077 · 35mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Riva-Risedronate · DIN 02341077 Manufacturer: Laboratoire Riva Inc.; listing date 2021-08-31 Health Canada: Marketed since 2010-07-28 · brand RIVA-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Laboratoire riva inc. · schedule Prescription

Check this DIN again · Health Canada product record

Riva-Risedronate: Formulary list price $1.6764/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.6764 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82662 · Verify on the e-Formulary ↗ (DIN 02341077)

Source record

DIN 02341077: Riva-Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000430; group id 952; item number 2261; lccId None; manufacturer id RIA Source form: Tab; strength: 35mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.6764; ministry $1.6764 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02341077 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82662

Interchangeable products

Actonel · DIN 02246896 · not recorded Apo-Risedronate · DIN 02353687 · $1.6764 Auro-Risedronate · DIN 02406306 · $1.6764 Jamp-Risedronate · DIN 02368552 · $1.6764 PMS-Risedronate · DIN 02302209 · $1.6764 Ratio-Risedronate · DIN 02319861 · $1.6764 Risedronate · DIN 02370255 · $1.6764 Risedronate · DIN 02411407 · $1.6764 Sandoz Risedronate · DIN 02327295 · $1.6764 Teva-Risedronate · DIN 02298392 · $1.6764

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02341077

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Risedronate · DIN 02327295 · 35mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Sandoz Risedronate · DIN 02327295 Manufacturer: Sandoz Canada Inc.; listing date 2010-10-28 Health Canada: Marketed since 2010-07-28 · brand SANDOZ RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Sandoz canada incorporated · schedule Prescription

Check this DIN again · Health Canada product record

Sandoz Risedronate: Formulary list price $1.6764/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.6764 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81259 · Verify on the e-Formulary ↗ (DIN 02327295)

Source record

DIN 02327295: Sandoz Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000430; group id 952; item number 2261; lccId None; manufacturer id SDZ Source form: Tab; strength: 35mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.6764; ministry $1.6764 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02327295 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81259

Interchangeable products

Actonel · DIN 02246896 · not recorded Apo-Risedronate · DIN 02353687 · $1.6764 Auro-Risedronate · DIN 02406306 · $1.6764 Jamp-Risedronate · DIN 02368552 · $1.6764 PMS-Risedronate · DIN 02302209 · $1.6764 Ratio-Risedronate · DIN 02319861 · $1.6764 Risedronate · DIN 02370255 · $1.6764 Risedronate · DIN 02411407 · $1.6764 Riva-Risedronate · DIN 02341077 · $1.6764 Teva-Risedronate · DIN 02298392 · $1.6764

Shortage status: resolved shortage (ended 2024-03-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02327295

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Risedronate · DIN 02298392 · 35mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Teva-Risedronate · DIN 02298392 Manufacturer: Teva Canada Limited; listing date 2010-04-23 Health Canada: Marketed since 2011-06-03 · brand TEVA-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM MONOHYDRATE) 35 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Teva-Risedronate: Formulary list price $1.6764/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.6764 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 02298392: Teva-Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000430; group id 952; item number 2261; lccId None; manufacturer id TEV Source form: Tab; strength: 35mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.6764; ministry $1.6764 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02298392 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78369

Interchangeable products

Actonel · DIN 02246896 · not recorded Apo-Risedronate · DIN 02353687 · $1.6764 Auro-Risedronate · DIN 02406306 · $1.6764 Jamp-Risedronate · DIN 02368552 · $1.6764 PMS-Risedronate · DIN 02302209 · $1.6764 Ratio-Risedronate · DIN 02319861 · $1.6764 Risedronate · DIN 02370255 · $1.6764 Risedronate · DIN 02411407 · $1.6764 Riva-Risedronate · DIN 02341077 · $1.6764 Sandoz Risedronate · DIN 02327295 · $1.6764

Shortage status: resolved shortage (ended 2024-02-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02298392

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Actonel · DIN 02316838 · 150mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Actonel · DIN 02316838 Manufacturer: Warner Chilcott Canada Co.; listing date 2009-06-23 Health Canada: Marketed since 2025-05-05 · brand ACTONEL · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 150 MG · company Abbvie corporation · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $11.1875 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80233 · Verify on the e-Formulary ↗ (DIN 02316838)

Source record

DIN 02316838: Actonel Raw flags: chronicUseMed=Y, sec3=Y Item: 920000595; group id 952; item number 2262; lccId None; manufacturer id WAR Source form: Tab; strength: 150mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $47.3370; ministry $11.1875 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02316838 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80233

Interchangeable products

Apo-Risedronate · DIN 02377721 · $11.1875 Auro-Risedronate · DIN 02442760 · $11.1875 PMS-Risedronate · DIN 02424177 · $11.1875 Risedronate · DIN 02528460 · $11.1875 Teva-Risedronate · DIN 02413809 · $11.1875

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Risedronate · DIN 02377721 · 150mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Apo-Risedronate · DIN 02377721 Manufacturer: Apotex Inc.; listing date 2012-06-26 Health Canada: Marketed since 2012-05-17 · brand APO-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 150 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Risedronate: Formulary list price $11.1875/unit (unit not stated in source; not the patient's cost)

Ministry pays: $11.1875 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86354 · Verify on the e-Formulary ↗ (DIN 02377721)

Source record

DIN 02377721: Apo-Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000595; group id 952; item number 2262; lccId None; manufacturer id APX Source form: Tab; strength: 150mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $11.1875; ministry $11.1875 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02377721 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86354

Interchangeable products

Actonel · DIN 02316838 · $11.1875 Auro-Risedronate · DIN 02442760 · $11.1875 PMS-Risedronate · DIN 02424177 · $11.1875 Risedronate · DIN 02528460 · $11.1875 Teva-Risedronate · DIN 02413809 · $11.1875

Shortage status: resolved shortage (ended 2022-03-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02377721

Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Risedronate · DIN 02424177 · 150mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

1 brand, same coverage

PMS-Risedronate · DIN 02424177 Manufacturer: Pharmascience Inc.; listing date 2014-07-30 Health Canada: Marketed since 2014-05-28 · brand PMS-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 150 MG · company Pharmascience inc · schedule Prescription

Check this DIN again · Health Canada product record

PMS-Risedronate: Formulary list price $11.1875/unit (unit not stated in source; not the patient's cost)

Ministry pays: $11.1875 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90889 · Verify on the e-Formulary ↗ (DIN 02424177)

Source record

DIN 02424177: PMS-Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000595; group id 952; item number 2262; lccId None; manufacturer id PMS Source form: Tab; strength: 150mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $11.1875; ministry $11.1875 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02424177 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90889

Interchangeable products

Actonel · DIN 02316838 · $11.1875 Apo-Risedronate · DIN 02377721 · $11.1875 Auro-Risedronate · DIN 02442760 · $11.1875 Risedronate · DIN 02528460 · $11.1875 Teva-Risedronate · DIN 02413809 · $11.1875

Shortage status: resolved shortage (ended 2020-03-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02424177

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Risedronate · DIN 02528460 · 150mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

1 brand, same coverage

Risedronate · DIN 02528460 Manufacturer: Sanis Health Inc.; listing date 2022-11-30 Health Canada: Marketed since 2022-10-05 · brand RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 150 MG · company Sanis health inc · schedule Prescription

Check this DIN again · Health Canada product record

Risedronate: Formulary list price $11.1875/unit (unit not stated in source; not the patient's cost)

Ministry pays: $11.1875 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101771 · Verify on the e-Formulary ↗ (DIN 02528460)

Source record

DIN 02528460: Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000595; group id 952; item number 2262; lccId None; manufacturer id SAI Source form: Tab; strength: 150mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $11.1875; ministry $11.1875 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02528460 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101771

Interchangeable products

Actonel · DIN 02316838 · $11.1875 Apo-Risedronate · DIN 02377721 · $11.1875 Auro-Risedronate · DIN 02442760 · $11.1875 PMS-Risedronate · DIN 02424177 · $11.1875 Teva-Risedronate · DIN 02413809 · $11.1875

Shortage status: resolved shortage (ended 2026-04-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02528460

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Risedronate · DIN 02413809 · 150mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

1 brand, same coverage

Teva-Risedronate · DIN 02413809 Manufacturer: Teva Canada Limited; listing date 2014-01-03 Health Canada: Marketed since 2013-10-10 · brand TEVA-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM MONOHYDRATE) 150 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Teva-Risedronate: Formulary list price $11.1875/unit (unit not stated in source; not the patient's cost)

Ministry pays: $11.1875 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89845 · Verify on the e-Formulary ↗ (DIN 02413809)

Source record

DIN 02413809: Teva-Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000595; group id 952; item number 2262; lccId None; manufacturer id TEV Source form: Tab; strength: 150mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $11.1875; ministry $11.1875 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02413809 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89845

Interchangeable products

Actonel · DIN 02316838 · $11.1875 Apo-Risedronate · DIN 02377721 · $11.1875 Auro-Risedronate · DIN 02442760 · $11.1875 PMS-Risedronate · DIN 02424177 · $11.1875 Risedronate · DIN 02528460 · $11.1875

Shortage status: resolved shortage (ended 2026-06-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02413809

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Actonel · DIN 02246896 · 35mg · tablet

Listed, not a benefitMarketed · checked 2026-09-02

StatusListed, not a benefit

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Actonel · DIN 02246896 Manufacturer: Warner Chilcott Canada Co.; listing date 2003-04-16 Health Canada: Marketed since 2025-03-05 · brand ACTONEL · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Abbvie corporation · schedule Prescription

Check this DIN again · Health Canada product record

Actonel: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71123 · Verify on the e-Formulary ↗ (DIN 02246896)

Source record

DIN 02246896: Actonel Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 920000430; group id 952; item number 2261; lccId None; manufacturer id WAR Source form: Tab; strength: 35mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02246896 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71123

Interchangeable products

Apo-Risedronate · DIN 02353687 · $1.6764 Auro-Risedronate · DIN 02406306 · $1.6764 Jamp-Risedronate · DIN 02368552 · $1.6764 PMS-Risedronate · DIN 02302209 · $1.6764 Ratio-Risedronate · DIN 02319861 · $1.6764 Risedronate · DIN 02370255 · $1.6764 Risedronate · DIN 02411407 · $1.6764 Riva-Risedronate · DIN 02341077 · $1.6764 Sandoz Risedronate · DIN 02327295 · $1.6764 Teva-Risedronate · DIN 02298392 · $1.6764

Shortage status: resolved shortage (ended 2019-10-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02246896

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Risedronate · DIN 02442760 · 150mg · tablet

General benefitDormant since 2020-07-24 · checked 2026-09-02 · What does dormant mean?

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

1 brand, same coverage

Auro-Risedronate · DIN 02442760 Manufacturer: Auro Pharma Inc.; listing date 2018-04-30 Health Canada: Dormant since 2020-07-24 · brand AURO-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 150 MG · company Auro pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Auro-Risedronate: Formulary list price $11.1875/unit (unit not stated in source; not the patient's cost)

Ministry pays: $11.1875 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92715 · Verify on the e-Formulary ↗ (DIN 02442760)

Source record

DIN 02442760: Auro-Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000595; group id 952; item number 2262; lccId None; manufacturer id AUR Source form: Tab; strength: 150mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $11.1875; ministry $11.1875 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02442760 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92715

Interchangeable products

Actonel · DIN 02316838 · $11.1875 Apo-Risedronate · DIN 02377721 · $11.1875 PMS-Risedronate · DIN 02424177 · $11.1875 Risedronate · DIN 02528460 · $11.1875 Teva-Risedronate · DIN 02413809 · $11.1875

Shortage status: active shortage (reported 2019-03-05, last updated 2019-03-06) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02442760

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Dormant since 2020-07-24 — choose a marketed DIN from the same-category list.

Jamp-Risedronate · DIN 02368552 · 35mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2022-09-06 — choose a marketed DIN from the same-category list.Discontinued 2022-09-06 · checked 2026-09-02

StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-09-06 — choose a marketed DIN from the same-category list.

Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-09-06 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Jamp-Risedronate · DIN 02368552 Manufacturer: Jamp Pharma Corporation; listing date 2012-08-27 Health Canada: Cancelled post market since 2022-09-06 · brand JAMP-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Jamp pharma corporation · schedule Prescription

Check this DIN again · Health Canada product record

Jamp-Risedronate: Formulary list price $1.6764/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.6764 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85353 · Verify on the e-Formulary ↗ (DIN 02368552)

Source record

DIN 02368552: Jamp-Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000430; group id 952; item number 2261; lccId None; manufacturer id JPC Source form: Tab; strength: 35mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.6764; ministry $1.6764 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02368552 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85353

Interchangeable products

Actonel · DIN 02246896 · not recorded Apo-Risedronate · DIN 02353687 · $1.6764 Auro-Risedronate · DIN 02406306 · $1.6764 PMS-Risedronate · DIN 02302209 · $1.6764 Ratio-Risedronate · DIN 02319861 · $1.6764 Risedronate · DIN 02370255 · $1.6764 Risedronate · DIN 02411407 · $1.6764 Riva-Risedronate · DIN 02341077 · $1.6764 Sandoz Risedronate · DIN 02327295 · $1.6764 Teva-Risedronate · DIN 02298392 · $1.6764

Shortage status: active shortage (reported 2019-11-01, estimated to end 2022-12-30, last updated 2021-04-07) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02368552

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2022-09-06 — choose a marketed DIN from the same-category list.

Ratio-Risedronate · DIN 02319861 · 35mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2015-10-26 — choose a marketed DIN from the same-category list.Discontinued 2015-10-26 · checked 2026-09-02

StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2015-10-26 — choose a marketed DIN from the same-category list.

Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2015-10-26 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Ratio-Risedronate · DIN 02319861 Manufacturer: Ratiopharm Inc.; listing date 2010-10-28 Health Canada: Cancelled post market since 2015-10-26 · brand RATIO-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Ratiopharm inc division of teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Ratio-Risedronate: Formulary list price $1.6764/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.6764 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80533 · Verify on the e-Formulary ↗ (DIN 02319861)

Source record

DIN 02319861: Ratio-Risedronate Raw flags: chronicUseMed=Y, sec3=Y Item: 920000430; group id 952; item number 2261; lccId None; manufacturer id RPH Source form: Tab; strength: 35mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.6764; ministry $1.6764 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02319861 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80533

Interchangeable products

Actonel · DIN 02246896 · not recorded Apo-Risedronate · DIN 02353687 · $1.6764 Auro-Risedronate · DIN 02406306 · $1.6764 Jamp-Risedronate · DIN 02368552 · $1.6764 PMS-Risedronate · DIN 02302209 · $1.6764 Risedronate · DIN 02370255 · $1.6764 Risedronate · DIN 02411407 · $1.6764 Riva-Risedronate · DIN 02341077 · $1.6764 Sandoz Risedronate · DIN 02327295 · $1.6764 Teva-Risedronate · DIN 02298392 · $1.6764

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2015-10-26 — choose a marketed DIN from the same-category list.

Actonel · DIN 02242518 · 5mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2019-01-04 — choose a marketed DIN from the same-category list.Discontinued 2019-01-04 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2019-01-04 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2019-01-04 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Actonel · DIN 02242518 Manufacturer: Warner Chilcott Canada Co.; listing date 2001-03-07 Health Canada: Cancelled post market since 2019-01-04 · brand ACTONEL · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 5 MG · company Allergan pharma co. · schedule Prescription

Check this DIN again · Health Canada product record

Actonel: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66266 · Verify on the e-Formulary ↗ (DIN 02242518)

Source record

DIN 02242518: Actonel Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 920000372; group id 952; item number 2259; lccId None; manufacturer id WAR Source form: Tab; strength: 5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242518 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66266

Interchangeable products

Teva-Risedronate · DIN 02298376 · $1.8445

Shortage status: active shortage (reported not recorded, last updated 2018-12-20) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242518

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2019-01-04 — choose a marketed DIN from the same-category list.

Actonel · DIN 02239146 · 30mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2019-01-04 — choose a marketed DIN from the same-category list.Discontinued 2019-01-04 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2019-01-04 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Actonel · DIN 02239146 Manufacturer: Warner Chilcott Canada Co.; listing date 2000-04-17 Health Canada: Cancelled post market since 2019-01-04 · brand ACTONEL · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 30 MG · company Allergan pharma co. · schedule Prescription

Check this DIN again · Health Canada product record

Actonel: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62602 · Verify on the e-Formulary ↗ (DIN 02239146)

Source record

DIN 02239146: Actonel Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 920000340; group id 952; item number 2260; lccId None; manufacturer id WAR Source form: Tab; strength: 30mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02239146 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62602

Interchangeable products

Teva-Risedronate · DIN 02298384 · $11.3807

Shortage status: discontinued (2017-01-20, reported by ALLERGAN PHARMA CO.); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02239146

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2019-01-04 — choose a marketed DIN from the same-category list.

Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

CLODRONATE DISODIUM

· 2 products · Listed, not a benefit (1), Limited Use, codes 280, 358, 359 (1) · strengths: 400mg · Cap

ETIDRONATE DISODIUM

· 2 products · Listed, not a benefit (1), Limited Use, codes 236, 237 (1) · strengths: 200mg · Tab

ZOLEDRONIC ACID

· 12 products · Limited Use, codes 319, 436, 523 (2), Off-Formulary Interchangeable, not an ODB benefit (10) · strengths: 5mg/100mL, 4mg/5mL · Inj Sol-100mL Pk (Preservative-Free), Inj Sol-5mL Pk (Preservative-Free)

PAMIDRONATE DISODIUM

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 3mg/mL, 6mg/mL, 9mg/mL · Inj Sol-10mL Vial

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

DENOSUMAB

· 8 products · Limited Use, codes 687, 688 (4), Limited Use, codes 686 (4) · strengths: 60mg/mL, 120mg/1.7mL · Inj Sol-1.0mL Pref Syr Pk (Preservative-Free), Inj Sol-Pref Syr, Inj Sol-Pref Syr (Preservative-Free), Inj Sol-Vial Pk, Inj Sol-Vial Pk (Preservative-Free)

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 92:00 and 75 more

Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.

Other drugs whose Health Canada label lists a similar indication: osteoporosis in men, osteoporosis in postmenopausal women

From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL ALENDRONATE & CHOLECALCIFEROL · General benefit 1 INDICATIONS FOSAVANCE® (alendronate sodium/cholecalciferol) is indicated for: • The treatment of osteoporosis in postmenopausal women. PM: https://pdf.hres.ca/dpd_pm/00071923.PDF; date not captured; DIN 02276429; fetched 2026-09-10 Product monograph • The treatment of osteoporosis in men. PM: https://pdf.hres.ca/dpd_pm/00071923.PDF; date not captured; DIN 02276429; fetched 2026-09-10 Product monograph RALOXIFENE HCL · Limited Use, codes 373 INDICATIONS AND CLINICAL USE APO-RALOXIFENE (raloxifene hydrochloride) is indicated for the treatment and prevention of osteoporosis in postmenopausal women. PM: https://pdf.hres.ca/dpd_pm/00002184.PDF; date not captured; DIN 02279215; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26

What the Health Canada label says it is for

1 INDICATIONS ACTONEL (risedronate sodium hemi-pentahydrate) is indicated for:  the treatment and prevention of osteoporosis in postmenopausal women1  the treatment of osteoporosis in men, to improve bone mineral density  the treatment and prevention of glucocorticoid-induced osteoporosis in men and women1  Paget's disease of bone1 ACTONEL DR (risedronate sodium hemi-pentahydrate) in indicated for:  The treatment of osteoporosis in postmenopausal women 1Although risedronate tablets 5 mg and 30 mg are available in the marketplace, ACTONEL is no longer marketed in the 5 mg and 30 mg strengths. It may be necessary to use alternate risedronate sodium products to achieve the appropriate dose. Postmenopausal Osteoporosis: In the treatment of osteoporosis in postmenopausal women at risk of fracture, ACTONEL and ACTONEL DR prevent vertebral and nonvertebral osteoporosis-related (fragility) fractures and increase bone mineral density (BMD) at all measured skeletal sites of clinical importance for osteoporotic fractures, including spine, hip, and wrist. Osteoporosis may be confirmed by the presence or history of osteoporotic fra… https://pdf.hres.ca/dpd_pm/00068139.PDF PM date: NOV 3, 2022 Source product: ACTONEL; DIN 02246896; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Teva-Risedronate · DIN 02298384 Shortage status: discontinued (2025-04-07, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02298384

Check this DIN again

Auro-Risedronate · DIN 02442760 Shortage status: active shortage (reported 2019-03-05, last updated 2019-03-06) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02442760

Check this DIN again

Jamp-Risedronate · DIN 02368552 Shortage status: active shortage (reported 2019-11-01, estimated to end 2022-12-30, last updated 2021-04-07) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02368552

Check this DIN again

Actonel · DIN 02242518 Shortage status: active shortage (reported not recorded, last updated 2018-12-20) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242518

Check this DIN again

Actonel · DIN 02239146 Shortage status: discontinued (2017-01-20, reported by ALLERGAN PHARMA CO.); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02239146

Check this DIN again

Health Canada: dormant products

Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Actonel: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote

Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote

Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026